Impact of Community Treatment With Ivermectin for the Control of Scabies on the Prevalence of Antibodies to Strongyloides stercoralis in Children

Michael Marks; Sarah Gwyn; Hilary Toloka; Christian Kositz; James Asugeni; Rowena Asugeni; Jason Diau; John M Kaldor; Lucia Romani; Michelle Redman-MacLaren; David MacLaren; Anthony W Solomon; David C W Mabey; Andrew C Steer; Diana Martin

doi:10.1093/cid/ciaa584

Impact of Community Treatment With Ivermectin for the Control of Scabies on the Prevalence of Antibodies to Strongyloides stercoralis in Children

Clin Infect Dis. 2020 Dec 15;71(12):3226-3228. doi: 10.1093/cid/ciaa584.

Authors

Michael Marks^{1

2}, Sarah Gwyn³, Hilary Toloka⁴, Christian Kositz¹, James Asugeni⁴, Rowena Asugeni⁴, Jason Diau⁴, John M Kaldor⁵, Lucia Romani⁵, Michelle Redman-MacLaren⁶, David MacLaren⁶, Anthony W Solomon^{1

2}, David C W Mabey^{1

2}, Andrew C Steer^{7

8

9}, Diana Martin³

Affiliations

¹ Clinical Research Department, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.
² Hospital for Tropical Diseases, University College London Hospitals NHS Trust, London, United Kingdom.
³ Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
⁴ Atoifi Adventist Hospital, Atoifi, Malaita Province, Solomon Islands.
⁵ Kirby Institute, University of New South Wales, Sydney, Australia.
⁶ College of Medicine and Dentistry, James Cook University, Cairns, Australia.
⁷ Department of Pediatrics, University of Melbourne, Melbourne, Australia.
⁸ Department of General Medicine, Royal Children's Hospital, Melbourne, Australia.
⁹ Tropical Diseases Research Group, Murdoch Children's Research Institute, Melbourne, Australia.

Abstract

The prevalence of antibodies to Strongyloides stercoralis was measured in 0-12-year-olds using a bead-based immunoassay before and after ivermectin mass drug administration (MDA) for scabies in the Solomon Islands. Seroprevalence was 9.3% before and 5.1% after MDA (P = .019), demonstrating collateral benefits of ivermectin MDA in this setting.

Keywords: Strongyloides; ivermectin; neglected tropical diseases; scabies.

Publication types

Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

MeSH terms

Animals
Child
Humans
Ivermectin / therapeutic use
Melanesia / epidemiology
Prevalence
Scabies* / drug therapy
Scabies* / epidemiology
Seroepidemiologic Studies
Strongyloides stercoralis*
Strongyloidiasis* / drug therapy
Strongyloidiasis* / epidemiology

Substances

Ivermectin

Abstract

Publication types

MeSH terms

Substances

Grants and funding